570 related articles for article (PubMed ID: 21199519)
21. Hepatitis C and steatosis.
Monto A
Semin Gastrointest Dis; 2002 Jan; 13(1):40-6. PubMed ID: 11944633
[TBL] [Abstract][Full Text] [Related]
22. [Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].
Lonardo A; Loria P; Adinolfi LE; Andreana A; Ruggiero G; Carulli N
Ann Ital Med Int; 2005; 20(1):10-22. PubMed ID: 15859390
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response.
Kumar D; Farrell GC; Fung C; George J
Hepatology; 2002 Nov; 36(5):1266-72. PubMed ID: 12395339
[TBL] [Abstract][Full Text] [Related]
24. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors.
Tsochatzis E; Papatheodoridis GV; Manesis EK; Chrysanthos N; Kafiri G; Petraki K; Hadziyannis E; Pandelidaki H; Zafiropoulou R; Savvas S; Koskinas J; Archimandritis AJ
Am J Gastroenterol; 2007 Mar; 102(3):634-41. PubMed ID: 17222326
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus-induced steatosis: an overview.
Negro F
Dig Dis; 2010; 28(1):294-9. PubMed ID: 20460926
[TBL] [Abstract][Full Text] [Related]
26. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
27. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
28. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C and steatosis.
Dev A; Patel K; McHutchison JG
Clin Liver Dis; 2004 Nov; 8(4):881-92, ix. PubMed ID: 15464660
[TBL] [Abstract][Full Text] [Related]
30. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4.
Ashour E; Samy N; Sayed M; Imam A
Clin Lab; 2010; 56(3-4):103-10. PubMed ID: 20476641
[TBL] [Abstract][Full Text] [Related]
31. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Bressler BL; Guindi M; Tomlinson G; Heathcote J
Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
[TBL] [Abstract][Full Text] [Related]
32. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.
Peng D; Han Y; Ding H; Wei L
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1082-8. PubMed ID: 18707599
[TBL] [Abstract][Full Text] [Related]
33. Hepatocyte steatosis in patients infected with genotype 1 hepatitis C virus.
Fierbinţeanu-Braticevici C; Mohora M; Tribus L; Petrişor A; Creţoiu SM; Creţoiu D; Usvat R; Ioniţă L
Rom J Morphol Embryol; 2010; 51(2):235-42. PubMed ID: 20495737
[TBL] [Abstract][Full Text] [Related]
34. Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.
del Campo JA; López RA; Romero-Gómez M
Dig Dis; 2010; 28(1):285-93. PubMed ID: 20460925
[TBL] [Abstract][Full Text] [Related]
35. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.
Hézode C; Roudot-Thoraval F; Zafrani ES; Dhumeaux D; Pawlotsky JM
J Viral Hepat; 2004 Sep; 11(5):455-8. PubMed ID: 15357652
[TBL] [Abstract][Full Text] [Related]
36. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
[TBL] [Abstract][Full Text] [Related]
37. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000
[TBL] [Abstract][Full Text] [Related]
38. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses.
Anty R; Gelsi E; Giudicelli J; Mariné-Barjoan E; Gual P; Benzaken S; Saint-Paul MC; Sadoul JL; Huet PM; Tran A
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):671-7. PubMed ID: 17625437
[TBL] [Abstract][Full Text] [Related]
39. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
40. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
